Prostate cancer is the most common form of cancer diagnosed in men in the U.S., with 179,000 new cases diagnosed in 2002 and 31,500 deaths are reported relating to this disease. The National Cancer Institute estimates that one in six men will develop prostate cancer in their lifetime, typically after the age of 55. With 29% of all cancers in men being prostate cancer, the incidence of the disease is comparable to that seen with breast cancer.
In most cases, prostate cancer produces little or no symptoms. The cancer usually grows very slowly and may remain confined to the gland for many years. It is not until the tumor has enlarged and pressed on the urethra or has spread to other areas of the body, such as the spine or the pelvic bones, will symptoms begin to appear. At that time, patients may experience incomplete bladder emptying, decreased urinary stream, urinary hesitancy, nocturia and pelvic pain.
Filed under: Cancer, Prostate cancer | Tagged: abarelix depot, barchytherapy, bicalutamide, Casodex, Causes, Diagnosis, Eligard, Eulexin, euprolide, flutamide, goserelin, Hormonal treatment, leuprolide, LHRH agonists, Lupron, Nilandron, nilutamide, Prognosis, Prostate cancer, prostate-specific antigen test, Symptoms, Viadur, Viadur DUROS, Zoladex | 2 Comments »
Healthreason.com 